Dashboard
Manage Tickers

STRO SUTRO BIOPHARMA, INC.

Nasdaq sutrobio.com


$ 0.82 $ -0.03 (-3.43 %)    

Tuesday, 14-Oct-2025 16:02:45 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 0.8
$ 0.82
$ 0.80 x 2,000
$ 0.87 x 2,000
$ 0.80 - $ 0.85
$ 0.52 - $ 4.60
417,468
na
67.82M
$ 2.14
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-25-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-06-2021 06-30-2021 10-Q
18 05-07-2021 03-31-2021 10-Q
19 03-18-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-16-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-15-2019 03-31-2019 10-Q
27 04-01-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

sutro-biopharma-reveals-an-organizational-restructuring-to-prioritize-the-advancement-of-its-three-adc-programs-and-research-and-development-collaborations-the-restructuring-is-expected-to-extend-the-companys-runway-into-at-least-mid-2027--restructuring-to-result-in-workforce-reduction-of-one-third-of-employees-co-on-track-to-advance-stro-004-into-clinic-this-year-with-initial-data-expected-in-2026
Sutro Biopharma Reveals An Organizational ...
09/29/2025 21:14:59

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc.

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/04/2025 21:13:45

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/20/2025 21:06:43

wells-fargo-maintains-equal-weight-on-sutro-biopharma-lowers-price-target-to-3
Wells Fargo Maintains Equal-Weight on Sutr...
08/12/2025 12:41:25

Wells Fargo analyst Derek Archila maintains Sutro Biopharma (NASDAQ:STRO) with a Equal-Weight and lowers the price target fr...

sutro-biopharma-to-continue-to-reorganize-restructuring-and-related-costs-for-deprioritzation-of-luvelta-program-expected-to-recognize-portion-in-2025
Sutro Biopharma To Continue To Reorganize ...
08/07/2025 21:38:15

sutro-biopharma-q2-eps-014-beats-045-estimate-sales-6374m-beat-1435m-estimate
Sutro Biopharma Q2 EPS $(0.14) Beats $(0.4...
08/07/2025 20:42:24

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.4...

sutro-biopharma-partners-with-fda-to-advance-standards-and-analytics-for-antibody-drug-conjugates-using-xpresscf-technology
Sutro Biopharma Partners With FDA To Advan...
07/22/2025 12:14:16

- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format ant...

piper-sandler-upgrades-sutro-biopharma-to-overweight-maintains-price-target-to-2
Piper Sandler Upgrades Sutro Biopharma to ...
06/16/2025 15:52:11

Piper Sandler analyst Edward Tenthoff upgrades Sutro Biopharma (NASDAQ:STRO) from Neutral to Overweight and maintains the pr...

sutro-biopharma-appoints-greg-chow-as-cfo-effective-june-2-2025
Sutro Biopharma Appoints Greg Chow As CFO,...
06/02/2025 12:08:58

b-of-a-securities-maintains-underperform-on-sutro-biopharma-lowers-price-target-to-08
B of A Securities Maintains Underperform o...
05/19/2025 17:58:09

B of A Securities analyst Tazeen Ahmad maintains Sutro Biopharma (NASDAQ:STRO) with a Underperform and lowers the price targ...

sutro-biopharma-q1-eps-091-misses-071-estimate-sales-1740m-beat-1161m-estimate
Sutro Biopharma Q1 EPS $(0.91) Misses $(0....
05/08/2025 20:42:41

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0...

demystifying-sutro-biopharma-insights-from-4-analyst-reviews
Demystifying Sutro Biopharma: Insights Fro...
04/29/2025 14:00:50

hc-wainwright--co-reiterates-neutral-on-sutro-biopharma-maintains-2-price-target
HC Wainwright & Co. Reiterates Neutral on ...
04/29/2025 10:51:03

HC Wainwright & Co. analyst Andres Maldonado reiterates Sutro Biopharma (NASDAQ:STRO) with a Neutral and maintains $2 pr...

sutro-biopharma-announces-poster-presentations-to-highlight-its-next-generation-exatecan-and-dual-payload-adc-programs-at-upcoming-american-association-for-cancer-research-april-25-30-in-chicago-illinois
Sutro Biopharma Announces Poster Presentat...
04/28/2025 20:07:53

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antib...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
04/25/2025 17:06:15

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
04/07/2025 17:05:50

hc-wainwright--co-downgrades-sutro-biopharma-to-neutral-lowers-price-target-to-2
HC Wainwright & Co. Downgrades Sutro Bioph...
03/17/2025 12:53:38

HC Wainwright & Co. analyst Andrew Fein downgrades Sutro Biopharma (NASDAQ:STRO) from Buy to Neutral and lowers the pric...

reported-saturday-sutro-highlights-late-breaking-refrme-o1-data-demonstrating-32-orr-and-96-dcr-with-optimized-luvelta-dosing-in-proc-patients
Reported Saturday, Sutro Highlights Late-B...
03/17/2025 07:07:48

Late-Breaking Oral Presentation Highlights:At the selected optimized dose (5.2 mg/kg), luvelta achieved an ORR of 32%1 and a di...

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
03/14/2025 17:05:44

penny-stock-sutro-biopharma-cuts-costs-refocuses-pipeline
Penny Stock Sutro Biopharma Cuts Costs, Re...
03/14/2025 16:09:17

Sutro Biopharma reported $62 million in 2024 revenue, down from $153.7 million in 2023, and announced a pipeline restructuring.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION